UNASSIGNED: @entity2151 reductase (RR) has been reported to be associated with several types of @entity5 while the expression and role of RR in @entity259 ( @entity259 ) has not been investigated. Here, we first examined the expression level of three RR subunit proteins ( @entity4736 , @entity16071 , and @entity25837 ) in @entity3557 ( @entity3557 ) and @entity189 ( @entity189 ) @entity1 samples by immunohistochemistry. The results showed that @entity4736 was higher expressed in 95.2  % @entity5 tissues compared with their adjacent normal tissues in 146 @entity3557 samples. The expression level of @entity4736 was positively correlated with T stage, lymph node @entity3 (LNM), @entity3 ( @entity3 ), and TNM stage in @entity3557 @entity1 . However, in 12 @entity189 samples, @entity4736 expression was negatively expressed in six cases. To further determine the biological role of @entity4736 in @entity259 , ectopic expression or siRNA-mediated knockdown of @entity4736 were carried out in the high-differentiated @entity259 cell line @entity15293 and the poor-differentiated @entity259 cell line SW579, respectively. In @entity15293 and @entity1 cells, overexpression and siRNA knockdown of @entity4736 demonstrated that @entity4736 promoted DNA synthesis and proliferation in both cell lines as shown by EdU incorporation and cell viability assays. However, @entity4736 enhanced cell migration and invasion in @entity15293 cells but inhibited that in @entity1 cells as shown by wound healing and transwell assays. Moreover, we also found that @entity4736 promoted @entity983 expression and reduced Akt phosphorylation in a RR-activity-independent manner in the low-differentiated @entity259 cells but not in the high-differentiated @entity259 cells. In contrast, @entity16071 expression was higher expressed in both @entity3557 and @entity189 @entity1 samples, consisting with its oncogenic role in other @entity5 . Therefore, we suggest that @entity4736 promotes @entity259 proliferation as a component of RR but may play a different role in the invasion and @entity3 of differently differentiated @entity259 through a non-RR pathway, which could be meaningful to precision treatment of @entity259 with RR inhibitors.

@entity2151 reductase large subunit M1 plays a different role in the invasion and @entity3 of @entity3557 and XXXX .

@entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid carcinoma', 'PTC'] @entity1 :: ('9606', 'Species') :: ['SW579', 'patient', 'patients'] @entity4736 :: ('6240', 'Gene') :: ['RRM1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['undifferentiated thyroid carcinoma', 'UTC'] @entity25837 :: ('50484', 'Gene') :: ['RRM2B'] @entity983 :: ('5728', 'Gene') :: ['PTEN'] @entity3 :: ('MESH:D009362', 'Disease') :: ['extrathyroidal invasion', 'metastasis', 'ETI'] @entity15293 :: ('53373', 'Gene') :: ['TPC-1'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinoma', 'TC', 'thyroid carcinomas'] @entity2151 :: ('CHEBI:26561', 'Chemical') :: ['Ribonucleotide'] @entity16071 :: ('6241', 'Gene') :: ['RRM2']
@entity189 :: (MESH:D002277,Disease) :: ['undifferentiated thyroid carcinoma']
